Skip to main content
Clinical Trials/JPRN-jRCTs061220052
JPRN-jRCTs061220052
Completed
Phase 2

An Exploratory Clinical Study of the Efficacy and Safety of Remimazolam in Dental Procedures Under Intravenous Sedation

Kana Oue0 sites30 target enrollmentAugust 30, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Kana Oue
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 30, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kana Oue

Eligibility Criteria

Inclusion Criteria

  • 1\. Those who undergoing dental treatment by Oral and Maxillofacial Reconstructive Surgery under intravenous sedation in Stress\-free dental outpatient setting
  • 2\. Age: between 18 and 65 years old. Sex: male and female
  • 3\. ASA\-PS: 1 or 2
  • 4\. BMI: 18\.5 kg/m2 or more, less than 30 kg/m2
  • 5\. Those who voluntarily provided written informed consent upon receiving sufficient explanation and understanding the content of the study

Exclusion Criteria

  • 1\. Heavy drinkers (equivalent to 60 g/day of pure alcohol)
  • 2\. Those with complications of drug abuse and dependence and alcohol dependence or a history of them
  • 3\. Those who regularly used benzodiazepines
  • 4\. Those with diseases in which benzodiazepines are contraindicated, such as those with acute angle closure glaucoma and myasthenia gravis, or a history of hypersensitivity to benzo diazepines
  • 5\. Those with severe psychiatric disorder
  • 6\. Those with structural brain disorder
  • 7\. Those without the ability to provide informed consent due to complications of dementia, etc.
  • 8\. Those treated for severe or poorly controlled (ASA PS class 3 or greater) respiratory diseases (bronchial asthma, etc.), cardiovascular disease (hypertension, etc.), neurological disorders (convulsions, etc.), digestive diseases, liver diseases, kidney disease, hematopoietic diseases, mental illness, endocrine diseases, etc. or with a history of them who were deemed ineligible for the study for security reasons by the principal investigator or sub\-investigator
  • 9\. Those who are pregnant or lactating women, and who may be pregnant or wish to have a baby
  • 10\. Principal investigators, employees of the institution, or their family members who are directly involved in this or other clinical research

Outcomes

Primary Outcomes

Not specified

Similar Trials